NCT03713866Recruiting
Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia
Peri-Procedural Transmural Electrophysiological Imaging of Scar-Related Ventricular Tachycardia
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to "block" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% "mappable" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome. The central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 17 Oct 2018
- Start date
- 1 Nov 2019
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- John Sapp
- Diseases
- Coronary artery disease
- NCT number
- NCT03713866
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Nov 2019 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a life expectancy less than 6 months or are listed for heart transplantation at time of inclusion
- New York Heart Association (NYHA) functional class IV
- Had ST wave elevation myocardial infarction within \< 1 month
- Unwilling or unable to undergo cardiac MRI scan AND unwilling or unable to undergo cardiac CT scan (e.g. contrast allergy).
Lab values
- Have estimated Glomerular Filtration Ratio (eGFR) less than 30
Other
- Are pregnant
- Are on IV inotropic agents
- Have any contraindication to catheter ablation (including but not limited to mechanical prosthetic aortic and mitral valves, known protruding Left Ventricular (LV) thrombus
Who the study is looking for
- One or more episodes of sustained monomorphic VT
- Referred for catheter ablation
- Previously implanted ICD
- Signed the patient informed consent form
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| QEII HSC Coordinator of this site? Confirm its status | Halifax | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.